Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome: A Randomized Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS)

Next Previous
X
Search
Trial Profile

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome: A Randomized Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptifibatide (Primary) ; Aspirin; Heparin; Low molecular weight heparins
  • Indications Acute coronary syndromes; Myocardial ischaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms EARLY-ACS
  • Sponsors Merck Sharp & Dohme; Schering-Plough

    • Most Recent Events

    • 28 Jan 2020 Results of post hoc, subanalysis, in the EARLY ACS, exploring the association between morphine and ischemic events (n=5,438) in patients treated with concomitant clopidogrel, with Patients not treated with clopidogrel (n = 3,462) are used as negative controls,presenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) published in the Journal of the American College of Cardiology
    • 09 Nov 2012 Planned number of patients changed from 9500 to 10500 as reported by European Clinical Trials Database record.
    • 30 Mar 2009 Results presented at the American College of Cardiology meeting and reported in the New England Journal of Medicine, as reported by Schering-Plough.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top